EcoDrugPlus

Lck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMLUG00000006477
Gene Symbol: LCK
2 Cross references
120 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMLUG00000014860
Gene Symbol: LYN
2 Cross references
202 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSMLUG00000009423
Gene Symbol: MALT1
2 Cross references
195 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSMLUG00000001421
Gene Symbol: MAPKAPK2
2 Cross references
233 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 1

Ensembl ID : ENSMLUG00000007816
Gene Symbol: MKNK1
2 Cross references
167 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSMLUG00000008571
Gene Symbol: MKNK2
2 Cross references
220 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSMLUG00000009997
Gene Symbol: MDM2
2 Cross references
262 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSMLUG00000007884
Gene Symbol: MET
2 Cross references
211 Possible Orthologues:

Mpl Proto-Oncogene, Thrombopoietin Receptor

Ensembl ID : ENSMLUG00000012597
Gene Symbol: MPL
2 Cross references
186 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSMLUG00000003950
Gene Symbol: MLST8
2 Cross references
201 Possible Orthologues:

Nad(P)h Quinone Dehydrogenase 1

Ensembl ID : ENSMLUG00000014157
Gene Symbol: NQO1
2 Cross references
195 Possible Orthologues:

Nadph Oxidase 4

Ensembl ID : ENSMLUG00000016907
Gene Symbol: NOX4
2 Cross references
151 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).